Pembrolizumab + BCG

Merck's KEYNOTE-676 trial (NCT03711032) tests whether adding pembrolizumab (Keytruda) to standard BCG intravesical therapy improves outcomes in high-risk non-muscle invasive bladder cancer, the most common presentation of bladder cancer [1]. The Phase 3 interim analysis was positive for event-free survival in 2024, and Merck is moving toward regulatory filing [2]. If approved, this becomes the first checkpoint inhibitor used alongside BCG in front-line NMIBC - a population where BCG alone fails roughly 30-40% of patients.

Neither drug here is new. Pembrolizumab is the best-selling oncology drug on Earth, generating approximately $25 billion in 2024 revenue across more than 40 approved cancer indications [3]. BCG, marketed as TICE BCG, has been the standard intravesical treatment for HR-NMIBC since FDA approval in 1990 and remains one of the oldest immunotherapies in routine clinical use [4]. Pembrolizumab also carries an accelerated approval as monotherapy for BCG-unresponsive NMIBC with carcinoma in situ, based on the single-arm KEYNOTE-057 trial [5]. That indication is a different, later-stage population than KEYNOTE-676 targets. KEYNOTE-676 started enrolling in 2019 as a Phase 2/3 design. The Phase 2 portion generated encouraging complete response rates in the CIS cohort, and the Phase 3 portion expanded enrollment to power an event-free survival comparison against BCG alone. In 2024, an independent Data Monitoring Committee reviewed the interim analysis and found the combination had crossed its pre-specified efficacy boundary [2]. Merck has stated plans to file a supplemental Biologics License Application. The exact filing timeline has not been publicly confirmed as of early 2025, but given the positive readout and Merck's track record of rapid regulatory execution with Keytruda, a 2025 submission is plausible. The FDA is already familiar with pembrolizumab in bladder cancer, which removes some regulatory uncertainty around the combination's benefit-risk profile.

BCG - Bacillus Calmette-Guérin - is a live, weakened strain of the tuberculosis bacterium. When instilled directly into the bladder through a catheter, it sticks to the bladder lining and triggers a strong local immune response [4]. Think of it as a controlled bacterial alarm: the body sends T cells, natural killer cells, and macrophages (immune cells that engulf and destroy threats) rushing to the bladder wall. In the process, those immune cells also attack cancer cells growing in the lining. BCG has been doing this job since the late 1970s, and it works - but not well enough for everyone. The problem is that bladder tumors fight back. Many express a protein called PD-L1 on their surface. PD-L1 binds to PD-1, a receptor on T cells that functions like a brake pedal - when engaged, it tells the T cell to stand down [6]. So BCG can recruit an immune army to the bladder, but the tumor can still wave PD-L1 like a white flag that tricks those soldiers into holstering their weapons. Pembrolizumab blocks PD-1, removing that brake. The biological logic is clean: BCG sounds the alarm and recruits immune cells; pembrolizumab prevents the tumor from shutting them down. Translational data supports this - BCG treatment actually upregulates PD-L1 expression on tumor cells, which may limit BCG's own efficacy and simultaneously create a target for PD-1 blockade [6][7]. In other words, BCG may be partially defeating itself by provoking the very immune escape mechanism pembrolizumab is designed to block. The combination attacks both sides of that problem.

KEYNOTE-676 (NCT03711032) is a Phase 2/3, randomized, open-label trial comparing pembrolizumab plus BCG versus BCG alone in patients with HR-NMIBC [1]. The study enrolled patients with high-grade Ta, T1, or carcinoma in situ (CIS - flat, high-grade cancer confined to the bladder surface) who were either receiving BCG for the first time or had recurred after prior BCG but were not yet classified as BCG-unresponsive. That distinction is important: BCG-unresponsive patients represent a different, harder-to-treat population with separate therapeutic options. In the treatment arm, patients receive pembrolizumab 200 mg IV every three weeks alongside standard BCG intravesical instillations (induction followed by maintenance). The control arm receives BCG alone on the same intravesical schedule. The primary endpoint is event-free survival (EFS), defined as freedom from high-grade recurrence, progression to muscle-invasive disease, radical cystectomy, or death. This is the right endpoint because the real question in NMIBC is whether you can keep patients off the operating table - radical cystectomy (complete bladder removal) fundamentally changes quality of life, and avoiding or delaying it is the therapeutic goal. The trial enrolled approximately 800-1,000 patients across global sites. The open-label design is a minor weakness - both patients and investigators know the treatment assignment - but blinding intravesical therapy is logistically difficult, and the primary endpoint includes objective measures like recurrence on biopsy that limit observer bias. The independent Data Monitoring Committee reviewed the pre-specified interim analysis and found the efficacy boundary was crossed, supporting the combination's benefit [2].

The model gives this drug a 50% chance of eventually being approved. That starts from a historical average of about 48% for Phase 3 drugs in this area, then gets adjusted using ten facts about the trial and its sponsor. The estimate goes up because the trial has more secondary endpoints than usual, larger-than-typical enrollment, and a light or open-label blinding design; it goes down because earlier-phase results were weak or limited. The remaining factors are close to average for this stage, so they don't shift the number much.

Worth watching closely. HR-NMIBC is a large, recurring patient population - roughly 75,000 new NMIBC diagnoses per year in the US, with a substantial fraction classified as high-risk. If even half are candidates for this combination, the revenue opportunity is meaningful incremental growth for a $25 billion franchise [3]. Merck has the sales force, the KOL relationships, and the payer negotiation muscle already in place from selling Keytruda across dozens of indications. The key data point to watch is the full Phase 3 publication with the magnitude of EFS improvement and detailed safety tables. That determines whether this is a standard-of-care shift or an option reserved for select patients. Conference presentations at ASCO or AUA in 2025 are the likely venues. Competitively, Merck has this front-line space largely to itself. The active competitors are clustered in the BCG-unresponsive setting, which is a different population. Cretostimogene (CG Oncology) is in Phase 3 for BCG-unresponsive patients [8]. Janssen's TAR-200 plus cetrelimab targets the same BCG-unresponsive niche [9]. Nadofaragene firadenovec (Adstiladrin) is already approved there. None of these directly compete with pembrolizumab plus BCG in front-line treatment. That empty competitive field is unusual in oncology and gives Merck first-mover advantage if approved. Genomic biomarker work in NMIBC is progressing and could eventually refine which patients benefit most from the combination, though no companion diagnostic is currently required [7]. Check back at the sBLA filing announcement and the PDUFA date - those will set the timeline for when this reaches patients.